GPCRs in Immuno-Oncology

Our approach

The immune system plays multiple roles among which the detection and  destruction of cancer cells. To escape immunosurveillance, tumors inactivate the immune system not only via direct contact through immune checkpoint system, but also by releasing immunosuppressive molecules in the tumor microenvironment. Such strategies lead the tumor to escape the immune system and limit the therapeutic effects of therapies based on immune checkpoint inhibitor.

We exploit a robust platform consisting in a cross validation process including preclinical and clinical data to identify and validate GPCRs targets involved in immunosurveillance mechanisms.

Selected GPCRs are supported by a science-driven rationale, and we design and launch small molecule or monoclonal antibody discovery programs dedicated to deliver best-in-class and first-in-class candidates to the clinic.

GPCRs and immunosuppression

GPCRs constitute a large family of membrane receptors having delivered numbers of marketed drugs. Recently, some GPCRs have emerged as playing a strategic pivotal role in immunosuppression triggered by tumors to bypass immune system as well as to escape immune checkpoint inhibitor treatments.

As an expert of GPCRs, Domain Therapeutics relentlessly dedicates its energy to discover and bring to the clinic innovative immunotherapies targeting GPCR as personalized medicine to answer the lack of efficient treatments for cancer patients.